This study sought to develop a rapid method for the detection of activating autoantibodies directed against the ␤ 1 -adrenoceptor (anti-␤ 1 -Abs) in patients with heart failure.
Over the past 2 decades, evidence has accumulated from both animal-based and patient-based studies that functionally active autoantibodies targeting the human ␤ 1 -adrenergic receptor (anti-␤ 1 -Abs) may play an important role in the development and clinical course of progressive cardiac dilatation and failure (1, 2) . The anti-␤ 1 -Abs were initially described in up to 50% of patients with Chagas' cardiomyopathy (3, 4) . Later, they also were detected in patients with myocarditis (5) , and in patients with chronic heart failure caused by ischemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) (5) (6) (7) . In DCM patients, anti-␤ 1 -Abs positivity has been linked to a more depressed left ventricular function (6), a higher prevalence of serious ventricular arrhythmias (8, 9) , and a higher incidence of sudden cardiac death (9) . The definition of antibody positivity, however, depended on highly divergent screening methods used in these studies (i.e., enzyme-linked immunosorbent assay [ELISA] with receptor peptides, Western blotting of heart tissues, functional assays with neonatal rat cardiomyocytes, or detection by surface plasmon resonance [6,7,9 -13] ). Until now, this issue has not been solved satisfactorily.
Previously, using a 3-step screening procedure composed of an ELISA with synthetic receptor peptides as well as immunofluorescence and cyclic adenosine monophosphate (cAMP) responses in cells expressing native human ␤-adrenergic receptors (␤-ARs), have screened 104 heart failure patients and 108 matched healthy control patients for functionally active anti-␤ 1 -Abs. According to this screening procedure, the prevalence of stimulating anti-␤ 1 -Abs was Ͻ1% in healthy patients, about 10% in ICM patients, and 26% in DCM patients (6) . Interestingly, the prospective follow-up of these patients over more than 10 years showed an almost 3-fold increased cardiovascular and allcause mortality risk in anti-␤ 1 -Abs-positive compared with antibody-negative DCM patients (14) . By contrast, no stimulating anti-␤ 1 -Abs were detected in patients with hypertensive or valvular heart disease (15) .
In our studies, the definition of functionally active anti-␤ 1 -Abs was based mainly on their effects on receptor-mediated signaling (i.e., their effects on cellular cAMP levels and on the activity of the cAMP-dependent protein kinase [PKA] ). Cyclic AMP is a universal second messenger of many G protein-coupled receptors, including the ␤-adrenergic receptor family. It exerts its effects via PKA, cAMP-gated ion channels, phosphodiesterases, and exchange proteins directly activated by cAMP (Epac1 and 2) (16) . In recent years, several fluorescence methods have been developed to measure cAMP in intact cells. Fluorescence resonance energy transfer (FRET) between green fluorescent protein variants fused to the regulatory and catalytic subunits of PKA has been described to study the spatio-temporal dynamics of cAMP in neurons (17) or cardiac myocytes (18) . More recently, we have reported the development of novel single-chain fluorescence indicators by fusing enhanced cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP) directly to the cAMP binding domain of Epac proteins, which allowed achievement of a higher sensitivity and better temporal resolution of the cAMP measurements (19, 20) . Here, we decided to take advantage of this novel tool to analyze the prevalence of functionally active anti-␤ 1 -Abs in a cohort of previously antibody-typed patients with heart failure caused by DCM or ICM, and to study the ability of ␤-blockers to inhibit anti-␤ 1 -Absinduced receptor activation.
Methods

cAMP measurements by Epac-FRET.
To establish a novel cell-based method for the detection of functional anti-␤ 1 -Abs, human embryonic kidney HEK293 cells stably expressing human ␤ 1 -AR (0.4 pmol/mg membrane protein) were transiently transfected with Epac1-based fluorescent cAMP sensor (Epac1-camps) using calcium phosphate precipitation. Twenty-four to 48 h after transfection, cAMP measurements were performed microscopically as described (19) . The cells were maintained in buffer A (144 mmol/l NaCl, 5 mmol/l KCl, 2 mmol/l CaCl 2 , 1 mmol/l MgCl 2 , 20 mmol/l HEPES, pH ϭ 7.3), supplemented with 50 nmol/l ICI 118551 (Sigma, Deisenhofen, Germany) to avoid cross-reactivity with the endogenous ␤ 2 -AR (approximately 0.1 pmol/mg according to binding assays, data not shown). The immunoglobulin G (IgG) preparations were diluted in the same buffer and added to the cells at 0.13 g/l protein concentration. (-)Isoproterenol (Sigma) was used to determine the maximal cAMP response. Blocking experiments. To determine relevant epitopes for the anti-␤ 1 -Abs, we incubated them with peptides (0.5 g/l) derived from the human ␤ 1 -EC I (AGRWEYGS-FFCELQ) and ␤ 1 -EC II sequences (ARAESDEAR-RCYNDPKCCDFVTNRE) (21) for 6 h at 4°C. A peptide corresponding to the ␤ 2 -EC II sequence (ATHQEAIN-CYANETCCDFFTNRE) (22) served to control for specificity. Cyclic AMP signals were then measured by Epac-FRET and compared with those of unblocked IgG preparations. To inhibit receptor signaling by functional anti-␤ 1 -Abs, we used the clinically relevant ␤-AR antagonists alprenolol, metoprolol (Sigma), bisoprolol (Merck, Darmstadt, Germany), and carvedilol (provided by Dr. S. Engelhardt). Patients and samples. The IgG preparations available from 77 previously analyzed patients with heart failure caused by DCM (n ϭ 55) or ICM (n ϭ 22) (6, 15) were included in the present study. Diagnosis of DCM had been based on a left ventricular end-diastolic volume Ͼ110 ml/m 2 and an ejection fraction Ͻ55% (determined by ventriculography) together with an exclusion of coronary heart disease (by angiography) (6) . No exposure to cardiotoxic substances, myocarditis, or other systemic heart disease was evident from medical history in these patients. At the time of sample acquisition, all patients had been in stable hemodynamic condition and none of them had received ␤-blocking agents or sympathomimetic substances. Table 1 summarizes the clinical and hemodynamic data of the patients (DCM, n ϭ 55; ICM, n ϭ 22) whose IgG preparations were analyzed. Control subjects (n ϭ 50) were selected from healthy blood donors, and matched for gender and age. All assays were carried out with IgG fractions isolated by caprylic acid precipitation and normalized to total IgG concentration (800 g/ml), as described previously (6, 15, 23) . For the assays, IgG prepared from anti-␤ 1 -EC II -positive Lewis/CrlBR rats with dilated immunecardiomyopathy (generated by immunization against a ␤ 1 -EC II /glutathione-S-transferase [GST] fusion protein), anti-␤ 1 -EC I antibodies prepared from Lewis rats immunized with a ␤ 1 -EC I /GST fusion protein, and IgG from corresponding isogenic anti-␤ 1 -Abs-negative rats served as positive or negative controls, respectively (24) . The study was approved by the Medical Ethics Committee of the University of Würzburg. Statistics. Data are presented as median (interquartile range) or absolute numbers (percent), as appropriate. In figures, data are shown as mean (SEM). Continuous data were analyzed by 1-way analysis of variance (blocking experiments) and the Student t test. Statistical analysis was performed using SPSS 13.0.1 (SPSS Inc., Chicago, Illinois). After confirming normal distribution of the measured FRET signals (by applying the Kolmogorov-Smirnov test), Gaussian distribution curves per subgroup were generated using Origin 6.1 (OriginLab Corp., Northampton, Massachusetts). All p values are reported 2-sided. A p value Ͻ0.05 was considered statistically significant.
Results
Detection of functionally active anti-␤ 1 -Abs with a fluorescent Epac-sensor. To determine the anti-␤ 1 -Abs via receptor-induced cAMP accumulation in ␤ 1 -AR expressing HEK293 cells, we used a recently developed fluorescent cAMP sensor (Epac1-camps). The sensor detects intracellular cAMP with high spatial and temporal resolution by changes in FRET between CFP and YFP fused to the cAMP binding site of Epac1 (Fig. 1A) . Compared with conventional radioimmunoassay (RIA) cAMP detection systems, the new FRET assay has an about 10-fold higher sensitivity, rendering this method suitable for the detection of small changes in intracellular cAMP levels (Fig. 1B) . To test whether this technology can be used to detect antibodies activating the ␤ 1 -AR, we used IgG fractions from anti-␤ 1 -EC II -positive Lewis/CrlBR rats with dilated immune cardiomyopathy and isogenic control [19] ). This extremely sensitive sensor is characterized by a high dynamic range at physiologically relevant cAMP concentrations 0.1 to 20 mol/l (which are covered by only 15% of the maximal cAMP-RIA signal), making minor cAMP changes previously undetected by conventional assays well detectable by Epac-FRET. (C) The immunoglobulin (Ig)G prepared from rats immunized with glutathione-S-transferase (GST) fusion proteins containing the first (EC I -immunized, center) or second extracellular loop of the human ␤ 1 -AR (EC II -immunized, right) were assayed for activity using human embryonic kidney HEK293 cells stably expressing human ␤ 1 -AR transfected with Epac1-camps, and compared with nonimmunized animals (control animals, left) to assess the reliability of the method. Representative FRET ratio traces of 1 of 6 independent experiments are presented (% corresponds to the relative change in YFP/CFP intensity ratio). The decrease in FRET reflects an increase in intracellular cAMP.
Clinical and Hemodynamic Data of Patients With DCM and ICM (Fig. 1C, right) . The FRET signal produced by these antibodies corresponded to about 75% of the maximal signal induced by isoproterenol (iso max ). Next, we tested the functional effects of rat antibodies generated by active immunization against the first ␤ 1 -EC loop (human) fused to bacterial GST. Interestingly, these rat anti-␤ 1 -EC I antibodies also stimulated cAMP production, but the FRET signals induced were significantly lower than those induced by rat anti-␤ 1 -EC II , yielding only approximately 40% of iso max (Fig. 1C, center) . The onset of both the anti-␤ 1 -EC II -provoked and the anti-␤ 1 -EC I -provoked responses occurred with an initial delay of 100 to 150 s compatible with slow binding kinetics of the antibodies and the resultant conformational rearrangement of the receptor molecule. These experiments with anti-␤ 1 -Abs generated in rats suggested that our novel method also might be suitable for the detection of anti-␤ 1 -Abs in patients.
High prevalence of anti-␤ 1 -Abs in DCM patients. We then analyzed IgG preparations that were available from previously antibody-typed DCM patients (n ϭ 55) (6) and healthy control patients (n ϭ 50) matched for gender and age. None of the IgG preparations from healthy control patients significantly altered Epac-FRET signals ( Fig. 2A,  left) . In contrast, IgG preparations from all 17 DCM patients previously judged anti-␤ 1 -Abs-positive induced a marked and rapid loss of FRET signals, indicating an increase in intracellular cAMP caused by ␤ 1 -AR activation (49.5 Ϯ 3.9% of iso max ; Absϩ) ( Fig. 2A, right) , similar to the responses obtained with activating rat anti-EC II -Abs. Surprisingly, we detected anti-␤ 1 -Abs also in 23 of 38 (60%) DCM patients formerly judged antibody-negative (Abs-) ( Fig. 2A, center) , but the cAMP signals induced by these antibodies were significantly lower than in the previous group (31.3 Ϯ 6.8%, p Ͻ 0.001 [Student t test]) ( Fig. 2A, center) . At first sight, their effects on cAMP production seemed to be comparable with those of lowactivating rat anti-␤ 1 -Abs, generated against the human ␤ 1 -EC I loop.
To perform a systematic analysis of the different (human) anti-␤ 1 -Abs-induced cAMP responses, we plotted distribution histograms of the amplitude of the FRET signals for DCM patients and for healthy control patients, respectively. In the latter, we observed a single peak Gaussian distribution of the FRET signals ranging from Ϫ13.0% to ϩ18.6% of iso max , with a mean value of 5.0 Ϯ 6.2%. Positivity was thus defined as a FRET signal above 2 SD of the mean value of healthy control patients (i.e., Ͼ17.4% [5.0% ϩ 2 ϫ 6.2%]). In contrast to the single peak Gaussian distribution of the healthy control patients, the histogram for DCM patients showed a multiple peak distribution pattern. Subsequent iteration of the respective FRET values assuming a multipeak Gaussian model produced the best fit for a 3-peak Gaussian distribution, yielding a R 2 ϭ 0.98 (R 2 ϭ 0.47 or 0.77 for the 1-or 2-peak Gaussian distribution, respectively). The 55 DCM patients tested were then grouped at the respective intersection points of the 3 calculated Gaussian curves (Fig. 2B) . Fifteen of 55 (28%) patients showed FRET signals below the lower intersection (cutoff) point of 18.2% FRET response and were thus grouped negative (Abs-); all those patients also had been correctly grouped Abs-using the former screening algorithm. The remaining n ϭ 40 of 55 (72%) patients were grouped at the upper intersection (cutoff) point of 41.9% FRET response as low (n ϭ 22 of 55, 40%) or high activators (n ϭ 18 of 55, 33%), respectively (Fig. 2B) . All (n ϭ 17) previously identified anti-␤ 1 -Abs-positive DCM patients and 1 patient unidentified with the former methodology were classified high activators, whereas all (n ϭ 22) low activators (18.2% Ͻ FRET signal Ͻ41.9%) had been judged Abs-with the former screening algorithm. In summary, the analysis of Epac-FRET signals from the first patient collective analyzed showed an anti-␤ 1 -Abs prevalence of more than 70% (n ϭ 40 of 55) in DCM, which is higher than obtained by the ELISA/ immunofluorescence/cAMP-RIA screening procedure (6) . It seems that the Absϩ group can be separated into 2 subgroups on the basis of the FRET data, which were classified as low activators (FRET amplitude 18.2% to 41.9% of iso max ) and high activators (FRET amplitude Ն42% of iso max ).
Next, we analyzed n ϭ 22 still available IgG preparations from a previously antibody-typed ICM collective (6, 15) . Five previously antibody-positive judged patients had anti-␤ 1 -Abs producing strong FRET signals in a range of those classified high activators (Fig. 2C) . In contrast, IgG preparations from the other 17 ICM patients (previously judged antibody-negative) did not produce any significant FRET signals, indicating that low-activator anti-␤ 1 -Abs probably are not a typical feature of ICM.
As a consequence, the 2 newly identified FRET-positive DCM populations were studied in more detail. Analyzing the concentration response relationship, we found that low-activator IgG, even at higher concentrations, did not induce cAMP levels of a similar order of magnitude as high-activator IgG (Fig. 2D) . This finding renders lower titers of anti-␤ 1 -Abs in sera of low activators an unlikely explanation for the lower cAMP response, but rather suggests a different mechanism of action of this type of anti-␤ 1 -Abs at the receptor level. High or low activating capacity defines anti-␤ 1 -Abs against different epitopes. As suggested by the data obtained with our rat anti-␤ 1 -Abs, one reason for qualitative differences between antibodies in terms of FRET activity might be differences in the receptor epitopes targeted by different anti-␤ 1 -Abs. Previously, the occurrence of functional anti-␤ 1 -Abs against ␤ 1 -EC II and ␤ 1 -EC I, but not ␤ 1 -EC III , has been reported in DCM patients (11) . In addition, functional anti-␤ 1 -Abs against the ␤ 1 -EC II and ␤ 1 -EC I epitopes have also been generated successfully in animals by immunization, suggesting a certain antigenicity of these 2 epitopes (25) . To analyze whether different targeted epitopes might account for high or low FRET activating capacities of the anti-␤ 1 -Abs detected in our DCM patients, we incubated them with synthetic peptides corresponding to ␤ 1 -EC II or to ␤ 1 -EC I and analyzed the blocking effect of each of these peptides. These experiments showed that FRET signals of high-activator IgG could be blocked specifically by peptides corresponding to ␤ 1 -EC II , 
Detection of ␤ 1 -Receptor Antibodies but not by peptides corresponding to ␤ 1 -EC I or by a control peptide derived from EC II of the ␤ 2 -AR (7 patients tested) (Figs. 3A and 3C) . Concentration-response analysis of the ␤ 1 -EC II peptide showed that the peptide concentrations used in our experiments (0.5 g/l) were able to produce a maximal inhibitory effect (Fig. 3E) . Although we could achieve a partial, about 50%, inhibition of high-activator IgG by ␤ 1 -EC II peptides alone, simultaneous blocking with EC I and EC II peptides did not achieve a further decrease in cAMP signals (Figs. 3C and 3D ). In contrast, low-activator IgG was inhibited only by ␤ 1 -EC I peptides (10 patients tested) (Figs. 3B and 3D ) and again, a combination of EC I and EC II peptides did not enhance inhibition (Figs. 3C and  3D ). All sera from DCM patients with functional anti-␤ 1 -Abs yielding cAMP signals near the cut-off value between no and low as well as low and high activators were studied in detail by such blocking experiments to ascertain the accuracy of our classification. The only patient previously judged AbsϪ with IgG eliciting strong Epac-FRET signals (45.4% FRET signal) was confirmed as having highactivator IgG autoantibodies blockable by ␤ 1 -EC II peptides. In addition, 2 patients with IgG yielding about 40% FRET response (39.9% and 40.1%, respectively; classified low activators according to the upper intersection point of 41.9%) were equally inhibited by the ␤ 1 -EC II peptide, whereas all the other low-activator IgG tested (n ϭ 20 of 55, Epac-FRET responses between 20% to 39%) were inhibited only by the ␤ 1 -EC I peptide. These data are consistent with the hypothesis that the differences in cAMP production of high and low activators most likely reflect the different epitopes targeted and different active receptor conformations induced. However, to address the question of whether the differences in type, target domain, and activating capacity of anti-␤ 1 -Abs might be prognostically (and thus clinically) relevant in the course of heart failure, a systematic screening of larger patient populations with the novel FRET method is needed. ␤-blockers do not fully abolish high-activator-induced cAMP signals. Blockade of sympathetic hormone receptors by ␤-receptor antagonists has proven beneficial in heart failure (26) . Thus, one possible strategy to combat functional anti-␤ 1 -Abs in antibody-positive patients might be the pharmacological neutralization of autoantibodymediated stimulatory effects (2) . Therefore, we analyzed the effects of a panel of clinically relevant ␤-receptor antagonists on anti-␤ 1 -Abs-mediated cAMP increases (i.e., antibodyinduced Epac-FRET signals) in our transfected cell system. Both ␤ 1 -selective (bisoprolol, metoprolol) and nonselective (alprenolol, carvedilol) beta-blockers largely diminished the anti-␤ 1 -EC II -induced cAMP production. ). These data suggest that the clinically available beta-blocking agents can only partially shield from the harmful high-activator antibody-induced cAMP production in anti-␤ 1 -EC II -positive patients, illustrating the need for novel, more specifically antibody-directed therapeutic strategies in heart failure. Interestingly, when bisoprolol was added to cells pretreated with EC II peptides, the stimulatory effect of highactivator anti-␤ 1 -EC II antibodies on cAMP production was fully blocked (Fig. 4D) , indicating a synergistic effect between receptor peptides and ␤-blockers. Such a combi- It is not yet clear how antibodies reacting with the extracellular loops of the ␤ 1 -AR affect receptor activity. In the ␤ 2 -AR, amino acids in the transmembrane helices III, V, and VI have been assigned an anchoring function for agonists (27) . The second extracellular loop of the receptor is predicted to form a ␤-hairpin, which partly dips down into the ligand binding site, and thus might influence receptor-ligand interactions to some extent (28) . The conformation of this hairpin is thought to be stabilized by cysteines situated in EC I and EC II . In the ␤ 2 -AR, it has been shown that reduction or mutation of one or several of these cysteines results indeed in a significant reduction of agonist and antagonist affinities (29) . Thus, in ␤-AR correct folding of the EC I and EC II loops may be essential for correct formation of the ligand binding pocket and might explain why antibodies directed against these loops can interfere with ligand binding, modulate receptor conformation, and thereby also modulate receptor activity (2, 30) . Diagnostic implications. Compared with the previously developed ELISA/immunofluorescence/cAMP-RIA procedure (6), the novel FRET-based method is simpler, less time consuming, and at least as precise (i.e., correctly identifying all patients previously considered anti-␤ 1 -EC IIpositive). The new method is based on detecting antibodyinduced increases in cAMP. This second messenger most likely accounts for the harmful effects provoked by activating anti-␤ 1 -Abs (1, 31) . In addition, by quantifying antibodyinduced cAMP signals, the novel assay allows differentiation between functional anti-␤ 1 -Abs classes (i.e., high and low activators), which are presumably characterized by their binding to distinct extracellular receptor domains. However, studies in larger patient populations will be required to confirm and elucidate further the relationship between epitopes recognized by autoantibodies (␤ 1 -EC I or ␤ 1 -EC II , respectively) and the extent of cAMP stimulation elicited by these antibodies. Furthermore, we cannot exclude in patients the occurrence of functionally relevant antibodies reacting with epitopes other than ␤ 1 -EC I or ␤ 1 -EC II (2, 25) . Such antibodies might, in fact, be less (or not at all) susceptible to the blocking peptides used in our study, and thus might have been missed by our approach. On the other hand, the novel FRET method now offers the possibility of testing a panel of different blocking peptides to identify other potential epitopes for functional receptor antibodies.
In summary, screening by Epac-FRET seems to represent a very sensitive single-step approach, allowing detection of different kinds of activating antibodies directed against the human ␤ 1 -AR. Therapeutic implications. In contrast to bisoprololsensitive low-activator anti-␤ 1 -Abs, neither ␤ 1 -selective nor nonselective beta-receptor antagonists could fully block the stimulatory effects of high-activator anti-␤ 1 -Abs: all betablockers tested inhibited anti-␤ 1 -EC II -mediated cAMP production only partially (60% to 70%), with carvedilol appearing to be more effective than the other substances. A possible explanation for this finding might be different (allosteric) mechanisms by which antibodies or antagonists act on the receptor. By binding to the extracellular loops distant from the agonist and antagonist ligand binding sites in the transmembrane core of the receptor, anti-␤ 1 -EC antibodies might in fact induce different types of conformational changes of the receptor molecule (1, 30) . In addition, we cannot exclude in patients the occurrence of functional antibodies reacting with epitopes other than the extracellular loops (2, 25) , thereby leading to a confirmation of the receptor that prevents effective binding of beta-blocking agents.
Although the inhibitory effects of ␤-AR antagonists may contribute to their clinical effectiveness in anti-␤ 1 -Abspositive heart failure patients, the only partial inhibition of anti-␤ 1 -EC II antibodies should further stimulate research in the field of specifically antibody-directed therapeutic strategies. In addition to beta-blocking agents, such strategies might intend to eliminate stimulating anti-␤ 1 -Abs by nonselective or selective immunoadsorption (32, 33) , by receptor-homologous peptides (similar to those used in the present pilot study), or by direct targeting of the autoantibody-producing B-cells themselves (34) . In addition, our data provide a rationale for a combination therapy with beta-blockers and receptor peptides assuming a synergistic effect of the 2 approaches because bisoprolol fully abolished the stimulatory effects of anti-␤ 1 -EC II antibodies
